Saturday, June 20, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,771
Drugs linked 4,798

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 874 of 1,261

  1. US 8431532

    FZD8 extracellular domains and FZD8 extracellular domain fusion molecules and treatments using same

    Five Prime Therapeutics, Inc. · Granted Apr 30, 2013 · Expires Apr 25, 2033

    granted

  2. US 8431626

    Disulfide monomers comprising ethylenically unsaturated norbornyl groups suitable for dental compositions

    The Regents of the University of Colorado · Granted Apr 30, 2013 · Expires Apr 25, 2033

    granted

  3. US 8431594

    Bridged bicyclic heteroaryl substituted triazoles useful as AXL inhibitors

    Rigel Pharmaceuticals, Inc. · Granted Apr 30, 2013 · Expires Apr 25, 2033

    granted

  4. US 8431690

    T cell receptors and related materials and methods of use

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Apr 30, 2013 · Expires Apr 25, 2033

    granted

  5. US 8431605

    Modulators of ATP-binding cassette transporters

    Vertex Pharmaceuticals Incorporated · Granted Apr 30, 2013 · Expires Apr 25, 2033

    granted

  6. US 8431615

    Dose forms

    Vertex Pharmaceuticals Incorporated · Granted Apr 30, 2013 · Expires Apr 25, 2033

    granted

  7. US 8431556

    C-21-keto lupane derivatives preparation and use thereof

    Vertex Pharmaceuticals Incorporated · Granted Apr 30, 2013 · Expires Apr 25, 2033

    granted

  8. US 8431561

    Methods and compositions for treatment of excess nitric oxide or cyanide toxicity

    The Regents of the University of California · Granted Apr 30, 2013 · Expires Apr 25, 2033

    granted

  9. US 8431558

    Compositions and methods for modification of biomolecules

    The Regents of the University of California · Granted Apr 30, 2013 · Expires Apr 25, 2033

    granted

  10. US 8431543

    Chitosan based polymer conjugate and a method for producing the same

    ENGENE, INC. · Granted Apr 30, 2013 · Expires Apr 25, 2033

    granted

  11. US 8431380

    Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof

    HALOZYME, INC. · Granted Apr 30, 2013 · Expires Apr 25, 2033

    granted

  12. CA 2852397

    UTILISATION DE GLYCOSAMINOGLYCANES SULFATES POUR AMELIORER LA BIODISPONIBILITE DU FACTEUR VIII

    CSL BEHRING GMBH [DE] · Granted Apr 25, 2013 · Expires Apr 20, 2033

    granted

  13. CA 2851057

    UTILISATION COMBINEE D'UN GLYCOSAMINOGLYCANE SULFATE ET D'UNE HYALURONIDASE POUR AMELIORER LA BIODISPONIBILITE DU FACTEUR VIII

    CSL BEHRING GMBH [DE] · Granted Apr 25, 2013 · Expires Apr 20, 2033

    granted

  14. US 8426425

    Aminopyrimidines useful as inhibitors of protein kinases

    Vertex Pharmaceuticals Incorporated · Granted Apr 23, 2013 · Expires Apr 18, 2033

    granted

  15. US 8426359

    Inhibitors of serine proteases, particularly HCV NS3-NS4A protease

    Vertex Pharmaceuticals Incorporated · Granted Apr 23, 2013 · Expires Apr 18, 2033

    granted

  16. US 8425907

    Methods for treating pruritus by administering an antibody that specifically binds human PAR2

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 23, 2013 · Expires Apr 18, 2033

    granted

  17. US 8426585

    Compounds comprising a spiro-ring

    SUNSHINE LAKE PHARMA CO., LTD. · Granted Apr 23, 2013 · Expires Apr 18, 2033

    granted

  18. US 8426574

    Identification of astrovirus VA1 associated with gastroenteritis in humans

    The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention · Granted Apr 23, 2013 · Expires Apr 18, 2033

    granted

  19. US 8426611

    7-azoniabicyclo[2.2.1]heptane derivatives, methods of production, and pharmaceutical uses thereof

    THERON PHARMACEUTICALS, INC. · Granted Apr 23, 2013 · Expires Apr 18, 2033

    granted

  20. US 8425653

    Plasmon mediated photoinduced synthesis of silver triangular bipyramids

    Northwestern University · Granted Apr 23, 2013 · Expires Apr 18, 2033

    granted

  21. US 8426474

    Antimicrobial wash and carrier solutions and uses thereof

    Teva Animal Health, Inc. · Granted Apr 23, 2013 · Expires Apr 18, 2033

    granted

  22. US 8425933

    Abuse-resistant oral dosage forms and method of use thereof

    Elite Laboratories, Inc. · Granted Apr 23, 2013 · Expires Apr 18, 2033

    granted

  23. US 8425930

    Prebiotic oligosaccharides

    The Regents of the University of California · Granted Apr 23, 2013 · Expires Apr 18, 2033

    granted

  24. US 8426188

    Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof

    The Board of Regents of the University of Texas System · Granted Apr 23, 2013 · Expires Apr 18, 2033

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.